NasdaqGS:TNXPBiotechs
Tonix Pharmaceuticals Holding (TNXP) Q4 Loss Deepens Community Concerns Despite Revenue Progress
Tonix Pharmaceuticals Holding (TNXP) just closed out FY 2025 with fourth quarter revenue of US$5.39 million, Basic EPS of a US$3.98 loss, and a net loss excluding extra items of US$46.91 million, putting fresh numbers around a business that is still firmly in investment mode. The company has seen quarterly revenue move from US$2.58 million and Basic EPS of a US$9.77 loss in Q4 2024 to US$5.39 million and Basic EPS of a US$3.98 loss in Q4 2025, giving investors a clearer view of how sales and...